PH12020552111A1 - Benzenesulfonamide compounds and their use as therapeutic agents - Google Patents
Benzenesulfonamide compounds and their use as therapeutic agentsInfo
- Publication number
- PH12020552111A1 PH12020552111A1 PH12020552111A PH12020552111A PH12020552111A1 PH 12020552111 A1 PH12020552111 A1 PH 12020552111A1 PH 12020552111 A PH12020552111 A PH 12020552111A PH 12020552111 A PH12020552111 A PH 12020552111A PH 12020552111 A1 PH12020552111 A1 PH 12020552111A1
- Authority
- PH
- Philippines
- Prior art keywords
- therapeutic agents
- benzenesulfonamide compounds
- benzenesulfonamide
- compounds
- tautomers
- Prior art date
Links
- 150000008331 benzenesulfonamides Chemical class 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010015037 epilepsy Diseases 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 abstract 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 abstract 1
- -1 as stereoisomers Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000028329 epileptic seizure Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684436P | 2018-06-13 | 2018-06-13 | |
| PCT/US2019/037011 WO2019241533A1 (en) | 2018-06-13 | 2019-06-13 | Benzenesulfonamide compounds and their use as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12020552111A1 true PH12020552111A1 (en) | 2021-08-02 |
Family
ID=67138087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12020552111A PH12020552111A1 (en) | 2018-06-13 | 2020-12-09 | Benzenesulfonamide compounds and their use as therapeutic agents |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10745392B2 (enExample) |
| EP (1) | EP3807281A1 (enExample) |
| JP (3) | JP7371029B2 (enExample) |
| KR (1) | KR102833674B1 (enExample) |
| CN (1) | CN112262142B (enExample) |
| AU (1) | AU2019285184B2 (enExample) |
| BR (1) | BR112020024729A2 (enExample) |
| CA (1) | CA3103600A1 (enExample) |
| CL (1) | CL2020003197A1 (enExample) |
| CR (1) | CR20200613A (enExample) |
| EA (1) | EA202092719A1 (enExample) |
| EC (1) | ECSP20079861A (enExample) |
| IL (1) | IL278949B2 (enExample) |
| JO (1) | JOP20200304A1 (enExample) |
| MA (1) | MA52888A (enExample) |
| MX (1) | MX2020013317A (enExample) |
| NI (1) | NI202000098A (enExample) |
| PE (1) | PE20211389A1 (enExample) |
| PH (1) | PH12020552111A1 (enExample) |
| SA (1) | SA520420768B1 (enExample) |
| SG (1) | SG11202011862PA (enExample) |
| UA (1) | UA127024C2 (enExample) |
| WO (1) | WO2019241533A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20250505T1 (hr) * | 2016-05-20 | 2025-06-20 | Xenon Pharmaceuticals Inc. | Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva |
| ES2967410T3 (es) | 2016-12-09 | 2024-04-30 | Xenon Pharmaceuticals Inc | Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos |
| CN112262142B (zh) * | 2018-06-13 | 2023-11-14 | 泽农医药公司 | 苯磺酰胺化合物及其作为治疗剂的用途 |
| MX2021001380A (es) | 2018-08-31 | 2021-05-27 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos. |
| EP4655291A2 (en) * | 2023-01-26 | 2025-12-03 | Merck Sharp & Dohme LLC | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels background |
| CN117510431A (zh) * | 2023-11-08 | 2024-02-06 | 浙江雅辰药物科技股份有限公司 | 一种异噻唑-3-酮及其衍生物、合成方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5877193A (en) | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| US6416780B1 (en) | 1997-05-07 | 2002-07-09 | Galen (Chemicals) Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| CA2349832A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| DE19907385A1 (de) | 1999-02-20 | 2000-08-24 | Boehringer Ingelheim Pharma | Neue substituierte 3-Phenoxy- und 3-Phenylalkyloxy-2-phenyl-propylamine |
| ES2208364T3 (es) | 1999-07-16 | 2004-06-16 | Warner-Lambert Company Llc | Procedimiento para tratar dolor cronico usando inhibidores de mek. |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| AU2003243921B2 (en) | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| JP2005162726A (ja) | 2003-01-24 | 2005-06-23 | Tanabe Seiyaku Co Ltd | ピラゾロピリミジン化合物およびその製法 |
| WO2004092123A2 (en) | 2003-04-10 | 2004-10-28 | Microbia, Inc. | Inhibitors of fungal invasion |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| EP1646628A1 (en) | 2003-07-08 | 2006-04-19 | Novartis AG | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
| EP1673357A2 (en) | 2003-08-08 | 2006-06-28 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| WO2006066109A2 (en) | 2004-12-17 | 2006-06-22 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| EP1937658A1 (en) | 2005-10-06 | 2008-07-02 | Sanofi-Aventis | 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| EP2316829A1 (en) | 2005-12-21 | 2011-05-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| WO2008019967A2 (en) | 2006-08-15 | 2008-02-21 | F. Hoffmann-La Roche Ag | Phenyl, pyridine and quinoline derivatives |
| CA2666624C (en) | 2006-10-19 | 2015-12-29 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| US8124610B2 (en) * | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
| WO2009012241A1 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| WO2009013171A2 (en) | 2007-07-24 | 2009-01-29 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| WO2009099177A1 (ja) | 2008-02-06 | 2009-08-13 | Taisho Pharmaceutical Co., Ltd. | アミノイミダゾール誘導体 |
| KR20110027657A (ko) | 2008-06-25 | 2011-03-16 | 다이이찌 산쿄 가부시키가이샤 | 카르복실산 화합물 |
| WO2010002956A2 (en) | 2008-07-01 | 2010-01-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| WO2010029300A1 (en) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Bis aromatic compounds for use in the treatment of inflammation |
| PE20120008A1 (es) | 2009-01-12 | 2012-01-24 | Icagen Inc | Derivados de fenoxi bencenosulfonamida |
| CA2804593C (en) | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
| KR101541086B1 (ko) | 2010-08-20 | 2015-08-03 | 허치슨 메디파르마 리미티드 | 피롤로피리미딘 화합물 및 그 용도 |
| MX2014001851A (es) | 2011-08-17 | 2014-10-24 | Amgen Inc | Inhibidores del canal de heteroarilo sodio. |
| IN2014CN02959A (enExample) | 2011-10-28 | 2015-07-03 | Merck Sharp & Dohme | |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| US9630929B2 (en) * | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| WO2013122897A1 (en) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| SG11201408284VA (en) | 2012-05-22 | 2015-02-27 | Xenon Pharmaceuticals Inc | N-substituted benzamides and their use in the treatment of pain |
| ES2798138T3 (es) | 2012-10-15 | 2020-12-09 | Dae Woong Pharma | Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos |
| CA2889378A1 (en) | 2012-10-26 | 2014-05-01 | Merck Sharp & Dohme Corp. | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
| US9388179B2 (en) | 2012-10-26 | 2016-07-12 | Merck Sharp & Dohme Corp. | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels |
| TW201443025A (zh) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| US9776995B2 (en) | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| GB201310542D0 (en) | 2013-06-13 | 2013-07-31 | Antabio Sas | Compounds |
| JP6407285B2 (ja) | 2013-09-09 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ調節因子 |
| AU2014318979B2 (en) | 2013-09-10 | 2019-03-28 | Chromocell Corporation | Sodium channel modulators for the treatment of pain and diabetes |
| CR20160296A (es) | 2013-11-27 | 2016-09-20 | Genentech Inc | Benzamidas sustituidas y métodos para usarlas |
| WO2015077905A1 (en) | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels |
| JP6337124B2 (ja) | 2013-12-23 | 2018-06-06 | パーデュー、ファーマ、リミテッド、パートナーシップ | インダゾール及びその使用 |
| CN106795149B (zh) | 2015-05-05 | 2019-09-24 | 上海海雁医药科技有限公司 | 双环取代的苯磺酰胺衍生物、其制法与医药上的用途 |
| EP3389654B1 (en) | 2015-12-18 | 2023-08-16 | Merck Sharp & Dohme LLC | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| US10442778B2 (en) | 2016-03-22 | 2019-10-15 | Merck Sharp & Dohme Corp. | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels |
| HRP20250505T1 (hr) | 2016-05-20 | 2025-06-20 | Xenon Pharmaceuticals Inc. | Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva |
| ES2897998T3 (es) | 2016-10-27 | 2022-03-03 | Bristol Myers Squibb Co | Inhibidores de la acilsulfonamida del NaV1.7 |
| US10968210B2 (en) * | 2016-11-17 | 2021-04-06 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| ES2967410T3 (es) * | 2016-12-09 | 2024-04-30 | Xenon Pharmaceuticals Inc | Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos |
| CN112262142B (zh) * | 2018-06-13 | 2023-11-14 | 泽农医药公司 | 苯磺酰胺化合物及其作为治疗剂的用途 |
| MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| MX2021001380A (es) | 2018-08-31 | 2021-05-27 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos. |
-
2019
- 2019-06-13 CN CN201980039029.1A patent/CN112262142B/zh active Active
- 2019-06-13 CA CA3103600A patent/CA3103600A1/en active Pending
- 2019-06-13 UA UAA202008102A patent/UA127024C2/uk unknown
- 2019-06-13 JP JP2020568796A patent/JP7371029B2/ja active Active
- 2019-06-13 SG SG11202011862PA patent/SG11202011862PA/en unknown
- 2019-06-13 WO PCT/US2019/037011 patent/WO2019241533A1/en not_active Ceased
- 2019-06-13 MA MA052888A patent/MA52888A/fr unknown
- 2019-06-13 IL IL278949A patent/IL278949B2/en unknown
- 2019-06-13 MX MX2020013317A patent/MX2020013317A/es unknown
- 2019-06-13 EA EA202092719A patent/EA202092719A1/ru unknown
- 2019-06-13 BR BR112020024729-4A patent/BR112020024729A2/pt unknown
- 2019-06-13 PE PE2020001990A patent/PE20211389A1/es unknown
- 2019-06-13 KR KR1020217000602A patent/KR102833674B1/ko active Active
- 2019-06-13 AU AU2019285184A patent/AU2019285184B2/en active Active
- 2019-06-13 US US16/440,459 patent/US10745392B2/en active Active
- 2019-06-13 CR CR20200613A patent/CR20200613A/es unknown
- 2019-06-13 EP EP19735024.2A patent/EP3807281A1/en active Pending
- 2019-12-13 JO JOP/2020/0304A patent/JOP20200304A1/ar unknown
-
2020
- 2020-07-13 US US16/927,178 patent/US11325902B2/en active Active
- 2020-12-09 PH PH12020552111A patent/PH12020552111A1/en unknown
- 2020-12-09 CL CL2020003197A patent/CL2020003197A1/es unknown
- 2020-12-10 NI NI202000098A patent/NI202000098A/es unknown
- 2020-12-10 EC ECSENADI202079861A patent/ECSP20079861A/es unknown
- 2020-12-10 SA SA520420768A patent/SA520420768B1/ar unknown
-
2023
- 2023-08-08 JP JP2023129150A patent/JP2023138672A/ja not_active Withdrawn
-
2025
- 2025-05-30 JP JP2025090964A patent/JP2025128218A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200337A1 (ar) | مركبات سولفوناميد بها استبدال بأريل غير متجانس واستخدامها كعوامل علاجية | |
| PH12020552111A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| TN2019000175A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| TN2018000385A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| PH12022550980A1 (en) | Small molecule degraders of helios and methods of use | |
| PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| JO3032B1 (ar) | مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية. | |
| MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| MX2023010303A (es) | Metodo de modulacion de las vias de se?alizacion de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol. | |
| PH12020551772A1 (en) | Oxo-substituted compound | |
| PH12020551297A1 (en) | Compounds having s1p5 receptor agonistic activity | |
| PH12020551734A1 (en) | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | |
| GEAP202416375A (en) | Pro drugs of pde10 compounds | |
| DOP2020000234A (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos | |
| GB202215434D0 (en) | BEnzimadazole compound for the treatment of metabolic disorders | |
| MA51146B1 (fr) | Composés hétérocycliques bicycliques substitués utilisés en tant qu'inhibiteurs de prmt5 |